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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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Despite the recent disappointing news about two fundamental
programs seeking Huntington’s disease treatments, significant
drug-discovery initiatives proceed steadily. They include two
major clinical trials: KINECT-HD, sponsored by Neurocrine
Biosciences, and PROOF-HD, backed by Prilenia Therapeutics.
As reported in Part I of this two-part series and a previous article,
Roche announced that it had halted dosing in its historic Phase 3
gene silencing clinical trial, followed by Wave Life Sciences’
revelation that a similar effort to reduce the level of mutant
huntingtin protein had fallen short.
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In all likelihood, these drug candidates – at least the current
version of them – will not become HD treatments.
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However, other candidates abound.
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“Our pipeline is full of hope,” said George Yohrling, Ph.D., the
chief scientific officer for the Huntington’s Disease Society of
America (HDSA), in a March 25 webinar held to address the
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devastating clinical trial news. “Our pipeline is deep and diverse.”
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The HD research community “has not put all their eggs” in the
Roche “basket,” Dr. Yohrling explained. “We know what causes
the disease, and it’s the expansion of the huntingtin gene and the
expression of this mutant protein. There is a wide array of
approaches that we are using to tackle that. We’re hopeful that one
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or many of them will prove efficacious and modify the course of
the disease.”
Advancing programs
Although two Wave drug compounds failed in early-stage trials,
the company plans to start a trial of a third compound later this
year.
Both Roche and Wave are scheduled to make the first scientific
presentations about their recent results this week at the greatly
anticipated 16th Annual HD Therapeutics Conference, April 2729, a virtual event because of the COVID-19 pandemic. The
research community is confident that a deep analysis of these
studies will guide its next steps in the quest for therapies.
Researchers and companies are investigating dozens of distinct
designs for the type of drug used by Roche and Wave, an antisense
oligonucleotide (ASO).
Using surgery to inject its drug directly into the brain, Uniqure has
started the first-ever HD gene therapy safety trial in a small
number of trial participants.
Triplet Therapeutics aims to start a Phase 1 clinical trial in the
second half of this year of a unique ASO targeted at stopping the
mutant huntingtin gene’s tendency for continued expansion with
age (click here to read more).
Genetic modification is not the only approach under study,
however. Several other firms have Phase 2 programs in the works
to treat symptoms and reduce disability due to HD, and Neurocrine
expects to complete KINECT-HD – its Phase 3 trial of a choreareducing drug called valbenazine – by year’s end. Chorea is the
involuntary movements that afflict many people with HD. (On
KINECT-HD, also click here.)
Two similar drugs for chorea – Xenazine and Austedo – are the
only HD drugs approved by the U.S. Food and Drug
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Administration (FDA). They do not stop progression of the
disease.
A big goal: helping HD people function normally
A second major study, called PROOF-HD, is currently underway,
led by the Huntington Study Group (HSG), and sponsored by
Prilenia. This is a Phase 3 trial (the final step before a drug can be
approved by the FDA) of a drug called pridopidine, which is
proposed to improve function in people in the early stages of HD.
PROOF-HD stands for “PRidopidine Outcome On Function In
Huntington Disease.”
The clinical trial investigators believe that, if tested successfully,
pridopidine would help early-stage HD-afflicted individuals
maintain the ability to function normally in five key areas:
occupation/employment, managing personal finances, performing
household chores, performing activities of daily life (such as
bathing and dressing), and the ability to live in a home
environment. These five domains comprise the Shoulson-Fahn
Total Functional Capacity Scale (TFC), developed almost 40 years
ago, and used daily in HD clinics and research studies since then.
“The bigger the effect, the better,” Prilenia CEO Michael Hayden,
M.D., Ph.D., said in an April 1 interview about pridopidine with
Evaluate Vantage. “But any significant change in TFC would be
regarded as meaningful. There’s never been a drug that has had
any impact on TFC.”
Dr. Hayden is one of the world’s foremost HD scientists (click
here to watch our 2011 interview at the Therapeutics Conference.)
Prior to founding Prilenia in 2018, Dr. Hayden served as the
president of global R&D and chief scientific officer at Teva
Pharmaceutical Industries, Ltd. from 2012-2017, where he
oversaw ongoing research on pridopidine. He is also a professor at
the University of British Columbia and a senior scientist at the
Centre for Molecular Medicine and Therapeutics, having mentored
over 100 graduate students.
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In a January 28 HDSA webinar, Sandra Kostyk, M.D., Ph.D., a
professor Ohio State University and the co-principal investigator
for PROOF-HD in the U.S., pointed out that individuals’ Total
Functional Capacity ranges from zero (severely reduced function)
to 13 (full function). In early and mid-early HD, people on average
lose about one point on the scale a year, she explained.
In later stages of the disease, TFC may be less reflective of the rate
of decline, Dr. Kostyk continued.

A slide from the January 2021 HDSA webinar on the PROOF-HD trial
illustrating the Total Functional Capacity Scale and the effect of
pridopidine (screenshot by Gene Veritas, aka Kenneth P. Serbin)

Stopping the house from burning down
As an HD gene carrier who saw his mother devastated by the
disease, I have most feared losing my ability to function normally.
In three previous clinical trials of pridopidine, carried out between
2008 and 2018, both the original developer of the drug and Teva
failed to achieve the goal of reducing HD persons’ difficulties with
both voluntary and involuntary movements. At that time, scientists
thought that pridopidine affected levels of dopamine, an important
chemical in the brain affecting movements in both HD and
Parkinson’s disease.
However, additional analysis (done after the trials) showed that
patients taking the study drug showed a slower decline in TFC
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than expected from previous studies. “In early patients with
Huntington disease we have shown that the functional capacity
may be maintained,” Dr. Hayden observed in a January HSG
podcast. “There also appears to be an improvement and less
deterioration in patients with early HD.”
Referring to research conclusions published in the Journal of
Huntington’s Disease last December and co-authored by Dr.
Hayden and five others, he asserted that the stabilized TFC results
were the “first time that this has ever been shown in any analysis
for any drug. This was exciting.” Significantly, the FDA accepts
TFC as a way of measuring drug efficacy in HD clinical trials, he
added.
Those observations now require confirmation in PROOF-HD, Dr.
Hayden said.
Also, he continued, pridopidine “appears to have beneficial effects
around protecting neurons,” whatever the injury might be. The
goal, he said, is to prevent these brain cells from dying – one of
the major symptoms of HD.
“You want to treat them before they've died,” he explained. “If
you're trying to stop a fire taking care of a house, you don't want
the house to be burned down. And that's why treating early
becomes effective because there are still injured neurons, but not
dead neurons.”
In the HDSA webinar, Dr. Kostyk referred to pridopidine as a
possible “disease-modifying intervention – something that slows
the course of the disease.” The data indicate that early-stage HD
patients could obtain “long-term beneficial effects” from an
approved pridopidine drug for five years or more, she said.
That could buy valuable time for older asymptomatic individuals
like me and the HD community in general as we await other genemodifying or huntingtin-lowering drugs.
Prilenia: seeking to soothe the impact of disease
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Dr. Hayden explained the name and goals of Prilenia: “Prilenia,
which comes from pri, as in pridopidine, and lenia, which comes
from the Greek, to sooth or to cure. It's an aspiration that we can
have some impact on soothing some aspects of this disease and
potentially others as well.”
Privately held and based in Israel and the Netherlands, in 2020
Prilenia raised $68.5 million to support PROOF-HD and also a
Phase 2/3 trial in sufferers of amytrophic lateral sclerosis (ALS).
The ALS trial is currently enrolling participants at 54 sites across
the US.
Pridopidine taken as a pill
For HD sufferers, Pridopidine has another major advantage:
whereas ASOs so far have been injected into the spine and
Uniqure’s drug has been infused via brain surgery, pridopidine in
the PROOF-HD trial is very conveniently dosed in a 45-milligram
pill – a hard gelatin capsule – taken twice daily (click here for
official details of the trial).
Pridopidine has been extensively studied in several previous
clinical trials over more than a decade, with more than 1,300
people taking the drug, most of them with Huntington’s, Dr.
Kostyk said. As a result, researchers have high confidence in its
safety, she added.
Other HD research projects and biopharmaceutical firms are
seeking so-called small molecule drugs that can enter cells easily
and be taken as a pill.
A key receptor in the brain
Dr. Hayden and his colleagues now believe that the benefits of
pridopine are due to its ability to activate the sigma-1 receptor
(S1R). “It’s highly selective and fairly potent,” Dr. Hayden
explained about the action of pridopidine on S1R in response to a
question that I posed about the drug’s basic mechanism during his
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presentation at the 27th Annual HSG Meeting (held online) in
October 2020.
Dr. Hayden observed further that ample data demonstrates that
activation of S1R leads to protection of neurons. Deficiencies in
S1Rs leads to disease. He cited the case of patients lacking the
S1R gene, resulting in juvenile onset ALS.
“The activation of the sigma-1 receptor has multiple mechanisms
of action that should lead to neuroprotection in HD and help
stabilize cell function,” stated Dr. Kostyk, noting that S1Rs are
plentiful in the striatum – the inner core of the brain where HD is
especially devastating – and in the cortex, the large outer area of
the brain in charge of thought, language, and consciousness.
“One could think of the role of S1R as being like that of a high
school guidance counselor,” Martha Nance, M.D., director of the
HDSA Center of Excellence at Hennepin HealthCare in
Minneapolis, MN, wrote me in an e-mail. “When the receptor is
turned on, materials, molecules, and traffic within the cell flow as
it should, and the cell stays healthy, much as the counselor helps
students in trouble to be safe, find resources to keep healthy, and
stay in school. Supporting S1R early in the course of HD might
help more brain cells to remain healthy and function well for
longer.”
A relatively easy trial seeking practical results
Initiated last October, PROOF-HD investigators hope to enroll a
total of 480 clinical trial volunteers by year’s end at 30 sites in the
U.S. and Canada and 30 more in Europe. Over 15 months, half
will get pridopidine, and half will get a placebo. Patients must
have a diagnosis of HD, be 25 or older (no upper age limit), and
have a TFC score of at least 7, in line with the project’s goal of
testing the drug in the earlier stages of the disease.
Participants will undergo measurements of their TFC, cognition,
quality of life, and motor symptoms (difficulties with voluntary
and involuntary movements). They will also get blood and safety
tests. All participants can take part in the potential extension of the
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trial, with everybody receiving the drug. Dr. Kostyk described
PROOF-HD as an “easy” trial, with no brain scans or spinal taps
(used in the Roche trial, for instance). The study design has been
adapted to accommodate the challenges posed by COVID-19.
PROOF-HD emphasizes practical results. “What’s most important
for us it to get an agent out that’s working,” Dr. Kostyk said, and
“not necessarily” the kinds of measurements used in other trials in
order to demonstrate how the drug works.
A separate trial might be designed later for later-stage HD-afflicted
individuals, Dr. Hayden said.
For more information on PROOF-HD, click here or call 800-4877671.
A potential major step forward
“Our overall goal is to get this agent FDA-approved as soon as
possible so that we can start using it in individuals affected by
Huntington’s disease,” said Dr. Kostyk. The more quickly patients
enroll in the study, the sooner it will be completed, hopefully by
late 2022 or early 2023. Because this is a Phase 3 trial, if it is
successful, the next step will be an application to the FDA for
approval as a drug that doctors can prescribe.
Andrew Feigin, M.D., the HSG chair and principal investigator in
the U.S. for PROOF-HD, said in the HDSA webinar that Prilenia
has also shown interest in a possible future trial involving presymptomatic individuals like me.
Past skepticism about pridopidine focused on the lack of hard
evidence that the drug could really slow HD progression (click
here to read more). However, that debate came before the
discovery of a clearer picture of pridopidine as a potential
protector of neurons.
As will all clinical trials, the Huntington's community will be
rooting for success in PROOF-HD. Although pridopidine may not
cure HD, enabling people to have a few more years of normal
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daily function would be a major step in the quest to manage this
complex disease.
Posted by Gene Veritas at 4:39 PM
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